ConicMeds is a biopharmaceutical company developing a family of innovative drug candidates (NanospacersTM) for the treatment of pathologies associated with cellular lipointoxication. The unique mode of action of NanospacersTM provides new therapeutic solutions to meet major public health challenges for which medical needs are not yet fully satisfied, as evidenced by the very high progression of respiratory and metabolic diseases throughout the world.
Lipointoxications are characterized by an accumulation of saturated fatty acids within the membranes of the cells of our body, which affects their proper functioning. These diseases include obstructive respiratory diseases, such as Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases (COPD), but also metabolic syndromes, responsible for Type 2 Diabetes, Hepatic Steatosis and certain cardiovascular diseases.
Confocal microscopy image of bronchial epithelial cells in the presence of a selective probe, which emission wavelength varies according to the membrane properties. A green color is characteristic of a weakly organized membrane (fluid) and a blue color of an ordered (rigid) membrane. As shown, lipointoxication in bronchial epithelial cells induces stiffening (decrease in fluidity) of the intracellular membranes.
Our NanospacerTM technology aims to counter the deleterious effects of lipointoxication by restoring, through the use of innovative drug candidates, the membrane properties necessary for the proper functioning of the cell. Our candidates have the unique property of inserting into the membranes and of reconfering the fluidity that the cell needs.
Incubation with our drug candidate CM-CF01, results in optimal membrane fluidity in lipointoxicated bronchial epithelial cells
Conicmeds Development enters the Investor Network Accelerator program of EIT Health (European Institute of Innovation and Technology) More...
For this publication, Amélie Bacle, former Post-doc in the Lab, received the honors of the British Company of Biologists! More...
ConicMeds is pleased to welcome Dr. Patrick Page as its new CEO More...
ConicMeds winner of the national innovation contest I-Lab organized by the French Ministry of Higher Education, Research and Innovation, in partnership with BPI France. More...
Discover the latest research from our Cooperative Laboratory with the University of Poitiers. More...
The Nanospacer technology, developed by ConicMeds for the treatment of the major symptoms associated with Cystic Fibrosis, has been presented at the 15th Basic Science Conference, organized by the ECFS (European Cystic Fibrosis Society), from 21-24 March 2018 in Loutraki (Greece). More...
Founded in 1431, the University of Poitiers is a fully multidisciplinary university that trains every year nearly 28,000 students. Innovative and open to the world, it mobilizes more 1,300 researchers and develops internationally recognized high-level research, in the fields of engineering sciences, including aeronautics and transport, health, environment, chemistry and humanities and social. More...
SATT Grand Centre (a “Technology Transfer Company”), is a simplified joint stock company founded on May 15, 2013 with €60M of funding over 10 years, as part of the Future Investments Programme (the Programme Investissements d’Avenir or “PIA”). SATT Grand Centre operates as a key point of contact and an interface between public research and industry to ensure the valorisation of research results, throughout the four regions in which it operates: Auvergne, Centre-Val de Loire, Limousin and Poitou-Charentes.
SATT Grand Centre has the task of simplifying, accelerating and facilitating technology transfers from public research to companies, regardless of their size or business sector. More...
Address :
1, rue George Bonnet
86000 Poitiers
France
E-mail :
contact@conicmeds.fr
© Conicmeds Development - All rights reserved
Legal Information and Disclaimer – Website created by Amélie Bacle
